ライフサイエンスコーパス: breathlessness

1 ment in elderly patients with effort-induced breathlessness.

2 current medication, history, and symptoms of breathlessness.

3 upling were the main determinants of reduced breathlessness.

4 conditions experience distinct qualities of breathlessness.

5 d the relationship between changes in DH and breathlessness.

6 eased synchronicity with the amygdala during breathlessness.

7 OPD) and an important contributing factor to breathlessness.

8 same as in men; more had shock, syncope, and breathlessness.

9 consistently reported increased feelings of breathlessness.

10 er pharmacologic interventions with improved breathlessness.

11 nonpharmacologic interventions with improved breathlessness.

12 reatment for adults with advanced cancer and breathlessness.

13 n symptoms that they may experience, such as breathlessness.

14 ants with CT abnormalities and/or persistent breathlessness.

15 rface between sensation and cognition during breathlessness.

16 moderate); most studies examined exertional breathlessness.

17 oses of extended-release morphine to relieve breathlessness.

18 the threat perception network for impending breathlessness.

19 e respiratory muscles and relates closely to breathlessness.

20 atients with advanced disease and refractory breathlessness.

21 y stop cycling due to leg effort rather than breathlessness.

22 recurrent episodes of coughing, wheezing and breathlessness.

23 roduced a significant reduction in perceived breathlessness.

24 The primary outcome measure was breathlessness (0-10 numerical rating scale [NRS]), meas

25 romboembolism (3.5%), joint pain (2.7%), and breathlessness (2.8%).

26 The occurrence of chest pain (9% vs 24%), breathlessness (21% vs 39%), and dizziness (6% vs 18%) a

27 ween the groups in end-exercise ventilation (breathlessness 25.7 L/min [16.3-32.0] vs leg fatigue 31.

28 onset, 63.2% of patients reported persistent breathlessness; 53.5%, significant fatigue; 37.5%, reduc

29 the cardiology department with complaints of breathlessness, abdominal pain and hematuria for the las

30 Acute cardiorespiratory breathlessness accounts for one in eight of all emergenc

31 significantly reduce the intensity of worst breathlessness after 1 week of treatment.

32 The variable origins of persistent breathlessness after coronavirus disease 2019 (COVID-19)

33 Patients reported higher breathlessness after SBT compared with nurses and physic

34 Often, in the context of breathlessness, aggressive cancer treatment is not benef

35 to allergens causes intermittent attacks of breathlessness, airway hyper-reactivity, wheezing, and c

36 Breathlessness alone was a more commonly cited limiting

37 enrolled consecutive adults with refractory breathlessness and advanced disease from three large tea

38 the elements subserving the consciousness of breathlessness and air hunger is limited.

39 ential confounders, the associations between breathlessness and airway obstruction at baseline and lo

40 obstruction showed similar associations with breathlessness and all-cause mortality, regardless of et

41 initial visit for patients who complained of breathlessness and at a second visit in a subgroup of pa

42 We also determined the association between breathlessness and demographic factors or respiratory ob

43 ber of individuals complain about continuing breathlessness and fatigue even months after the onset o

44 ce exercise capacity, cause symptoms such as breathlessness and fatigue, and, if severe, result in sy

45 umns of the periaqueductal grey (PAG) during breathlessness and its conditioned anticipation.

46 pulmonary disease (COPD) is limited by both breathlessness and leg muscle fatigue.

47 itation severity show similar predictions of breathlessness and mortality in the adult U.S. populatio

48 of airflow limitation in terms of exertional breathlessness and mortality in the general U.S. populat

49 LD 1-4 was calculated, and associations with breathlessness and mortality were analyzed by multinomia

50 ntiated from nonobstruction in terms of both breathlessness and mortality.

51 ous or nebulised MgSO(4) improve symptoms of breathlessness and reduce the need for hospital admissio

52 Some symptoms such as breathlessness and shortness of breath seem not to be ev

53 rmly fatal, and characterised by progressive breathlessness and unremitting pain in the chest wall.

54 cade of changes that lead to severe fatigue, breathlessness and, ultimately, death.

55 tating, with key symptoms including fatigue, breathlessness, and brain fog.

56 tating, with key symptoms including fatigue, breathlessness, and brain fog.

57 Clinical symptoms such as fatigue, breathlessness, and chest pain are frequently reported i

58 Moderate-to-severe difficulty thinking, breathlessness, and gastrointestinal symptoms were speci

59 function in patients with moderate or severe breathlessness, and no apparent relationship between bre

60 capnia, and exercise; breath-hold tolerance; breathlessness; and psychologic status.

61 -limbic correlations at rest, whereas during breathlessness anticipation, reduced functional synchron

62 oms, such as palpitations, chest discomfort, breathlessness, anxiety, and syncope, which significantl

63 gic interventions were compared, focusing on breathlessness, anxiety, exercise capacity, and health-r

64 The key outcomes reported in studies were breathlessness, anxiety, exercise capacity, health-relat

65 ual work.Conclusions: Airway obstruction and breathlessness are independently associated with prematu

66 There was a significant reduction in breathlessness as measured by Borg score (4.5 +/- 0.7 to

67 patients with diseases other than cancer and breathlessness as well as those with cancer.

68 uscles during inspiration (in-phase) reduces breathlessness associated with hypercapnia and resistive

69 The change in the intensity of worst breathlessness at week 1 was not significantly different

70 separate stimuli to produce mild to moderate breathlessness (BR): Protocol 1, steady-state hypercapni

71 urther the effect of chest wall vibration on breathlessness ("breathing discomfort") in patients, we

72 e symptoms were wheeze, waking at night with breathlessness, breathlessness following exercise, and w

73 -dose, extended-release morphine may relieve breathlessness, but evidence about its efficacy and dosi

74 measured pulmonary function tests, exercise breathlessness by Borg score, and exercise flow volume a

75 Mean evening breathlessness changed by -0.3 points (-0.7 to 0.1) in t

76 From baseline to day 6, mean morning breathlessness changed by -0.9 points (95% CI -1.3 to -0

77 hat leads to recurrent episodes of wheezing, breathlessness, chest tightness, and coughing.

78 his study were: to examine the decriptors of breathlessness chosen by a large sample of patients with

79 m scores on fatigue, postexertional malaise, breathlessness, cognitive difficulties, sleep problems,

80 tly decrease rates of hospital admission and breathlessness compared with placebo: intravenous MgSO(4

81 versus 11.0, P = 0.005), respiratory status (Breathlessness, Cough and Sputum Scale: 1.0 versus 0.0,

82 o -0.34]) and in moderate exacerbation risk, Breathlessness, Cough, and Sputum Scale, and 6MWD.

83 , -15.0 to -0.37]) and respiratory symptoms (Breathlessness, Cough, and Sputum Scale, beta, -0.8 [95%

84 airways manifesting with symptoms including breathlessness, cough, difficulty in breathing, and whee

85 S APT: wheeze after exercise; wheeze causing breathlessness; cough on exertion; current eczema and SP

86 Among people with COPD and severe chronic breathlessness, daily low-dose, extended-release morphin

87 trial including people with COPD and chronic breathlessness (defined as a modified Medical Research C

88 Change in VAS breathlessness did not differ between active treatments

89 of the nurses and physicians underestimated breathlessness (difference score, </=-2) compared with t

90 which is impaired gas exchange, resulting in breathlessness, diminished exercise tolerance, and decre

91 tium, resulting in compromised gas exchange, breathlessness, diminished quality of life (QoL), and ul

92 ese results suggest that patients limited by breathlessness due to ventilatory constraints can be ide

93 ssness, and no apparent relationship between breathlessness during the SBT and extubation outcome.

94 Asthma causes the unpleasant sensation of breathlessness (dyspnea) caused by airway obstruction.

95 Comparisons of breathlessness, exercise volumes, and pressures were mad

96 in respect to wheeze (F = 5.6, p < 0.01) and breathlessness (F = 6.05, p < 0.01).

97 s with COVID-19 still experience symptoms of breathlessness, fatigue, pain, reduced mobility, depress

98 atures of long-COVID (breathing difficulties/breathlessness, fatigue/malaise, chest/throat pain, head

99 re donation-related symptoms (eg, tiredness, breathlessness, feeling faint, dizziness, and restless l

100 wheeze, waking at night with breathlessness, breathlessness following exercise, and waking with cough

101 ected statements that described qualities of breathlessness from a 15-item questionnaire and complete

102 selected phrases that described qualities of breathlessness from a 15-item questionnaire.

103 rg scale, and the qualitative descriptors of breathlessness from a 19-item questionnaire were assesse

104 omes (9.0%; higher likelihood of presence of breathlessness, higher chronic obstructive pulmonary dis

105 The perceived intensity of exertional breathlessness (i.e. dyspnoea) is higher in older women

106 pharmacological interventions on alleviating breathlessness in adults with advanced cancer.

107 he benefits of medications for management of breathlessness in advanced cancer or reported harms.

108 nd, randomised, controlled ABCD (Alleviating Breathlessness in Cancer Patients with Dexamethasone) tr

109 hine is frequently prescribed for persistent breathlessness in chronic obstructive pulmonary disease

110 ine does not worsen sleepiness when used for breathlessness in COPD.

111 A lesser peak breathlessness in DLT recipients approached statistical

112 brain blood flow during acute CO(2)-induced breathlessness in humans.

113 ld be used to identify the possible cause of breathlessness in patients at 3 months after hospital di

114 There are reports of breathlessness in patients many months after infection.

115 Symptoms of breathlessness in patients with heart failure with prese

116 ants reporting symptoms of wheeze, cough, or breathlessness in the previous 12 months and who were no

117 air delivered by nasal cannula for relief of breathlessness in this population of patients.

118 interventions were associated with improved breathlessness, including fan therapy (standardized mean

119 teral PAG (lPAG), where activity scaled with breathlessness intensity ratings, revealing a potential

120 Breathlessness is a common and distressing symptom, whic

121 Breathlessness is a frequent and debilitating symptom in

122 Breathlessness is a prevalent and distressing symptom in

123 Chronic breathlessness is common in people with chronic obstruct

124 Symptoms are wide ranging, but breathlessness is common.

125 Patients' recall of their sensations of breathlessness is reliable and comparable to dyspnea wit

126 The sensation of breathlessness is the most threatening symptom of respir

127 ther a patient's recall of the experience of breathlessness is the same as that provoked by physical

128 tween groups of patients stopping because of breathlessness, leg fatigue, or both were assessed with

129 es from 2 instruments for self-assessment of breathlessness, Mahler's baseline dyspnea index (BDI) an

130 Our primary outcome was patient-reported breathlessness mastery, a quality of life domain in the

131 The breathlessness support service improved breathlessness mastery.

132 ng a questionnaire containing descriptors of breathlessness may help to establish a specific diagnosi

133 ients admitted to hospital within 7 days and breathlessness measured on a 100 mm visual analogue scal

134 ere able to differentiate patients with more breathlessness (measured by BDI and VAS for breathing) a

135 l randomized trial of 342 patients with IPF, breathlessness (Medical Research Council dyspnea scale s

136 less than 50% predicted, and incapacitating breathlessness (Medical Research Council dyspnoea scale

137 ores beyond Week 1, and associations between breathlessness, morphine, and questionnaire scores.

138 in walking distance <450 m), and substantial breathlessness (MRC dyspnoea score >/=3).

139 nced lung cancer reporting at least moderate breathlessness (n = 247) were enrolled in a randomized t

140 her in patients stopping exercise because of breathlessness (n=12, median EMGdi%max 75.7% [IQR 69.5-7

141 ienced by people with advanced cancer: pain, breathlessness, nausea and vomiting, and fatigue.

142 and relapsing-remitting, including fatigue, breathlessness, neurocognitive effects and dysautonomia.

143 o patients (62%) reported moderate or severe breathlessness (Numerical Rating Scales >/= 4).

144 ) for hospital admission and a change in VAS breathlessness of -2.6 mm (-7.0 to 1.8; p=0.253) compare

145 ) for hospital admission and a change in VAS breathlessness of 2.6 mm (-1.6 to 6.8; p=0.231) compared

146 ude the safety and association with improved breathlessness of several nonpharmacological interventio

147 outcome was change in the intensity of worst breathlessness on a numerical rating scale (score range,

148 c wheeze and slightly more nasal catarrh and breathlessness on exertion than nonsmokers.

149 ted with more effectiveness than placebo for breathlessness or anxiety (reported mean between-group d

150 -2 (identified by anosmia with either fever, breathlessness or cough) presented significantly higher

151 t patients reported no change in symptoms of breathlessness or fatigue during the titration phase.

152 ivities and 24 persistent symptoms including breathlessness (OR 3.43, 95% CI 3.29-3.58), palpitations

153 .74, p = 0.006) and having left a job due to breathlessness (OR = 2.72, 95% CI = 1.07-6.92, p = 0.036

154 om they would most like to improve (fatigue, breathlessness, pain, anxiety/depression or other) as th

155 ' 11-point Numerical Rating Scales scores of breathlessness, perception of feeling secure, and improv

156 sit 2 between descriptors for recall and for breathlessness provoked by walking was 68% (r = 0.69; p

157 the 1-minute sit-to-stand test and completed breathlessness questionnaires.

158 s confirmed by a correlational analysis with breathlessness ratings.

159 intained during exercise, and the associated breathlessness reflects the hyperventilation.

160 The median intensity of breathlessness reported by patients was five compared wi

161 2.89; 95% confidence interval, 1.80-4.65) or breathlessness (risk ratio, 3.07; 95% confidence interva

162 catheter) and expired gases, and ratings of breathlessness (RPB, Borg 0-10) were assessed.

163 using the Modified Medical Research Council Breathlessness scale and general fatigue using the Patie

164 ntial confounders: cancer versus non-cancer, breathlessness severity, presence of an informal caregiv

165 d by troublesome symptoms such as refractory breathlessness; short-term palliative care; and, in sett

166 ed on a score including 7 clinical features (breathlessness, sleep disturbance, cyanosis, venous dila

167 ore effectiveness than placebo for improving breathlessness (SMD, -0.14; 95% CI, -0.47 to 0.18) or ex

168 opioids did not differ in effectiveness for breathlessness (SMD, 0.15; 95% CI, -0.22 to 0.52) (SOE,

169 nting patients were randomly assigned (53 to breathlessness support service and 52 to usual care).

170 Mastery in the breathlessness support service group improved compared w

171 randomisation to 6 months was better in the breathlessness support service group than in the control

172 The breathlessness support service improved breathlessness m

173 allocated (1:1) patients to receive either a breathlessness support service or usual care.

174 The breathlessness support service was a short-term, single

175 ld be higher in patients stopping because of breathlessness than in those limited by leg fatigue.

176 le function may contribute to the feeling of breathlessness that has been well described in this pati

177 se patients with more severe and less severe breathlessness, the primary symptom of active alveolitis

178 Exertional breathlessness, the principal symptom of HF, has many ca

179 ompared with patients who did not experience breathlessness, those who did had significantly higher i

180 centres, both at rest and in the context of breathlessness threat.

181 a hallway to provoke a moderate intensity of breathlessness (to compare recall with direct experience

182 pically confirmed ILO patients to generate a Breathlessness Triggers Survey (BrTS).

183 The duration of breathlessness was also reduced by NIV (p=0.025).

184 Breathlessness was assessed in 296 (89%) patients alloca

185 Subjective breathlessness was manipulated while end-tidal CO(2-) wa

186 Perceived breathlessness was measured with the Borg Scale of Respi

187 Underestimation of breathlessness was not associated with professional comp

188 At outpatient review, persistent breathlessness was reported in 37 of the 80 participants

189 gical interventions associated with improved breathlessness were acupressure and reflexology (integra

190 years with self-reported current wheeze and breathlessness were identified from a random population

191 ventilation, peak heart rate, and perceived breathlessness were lower in KE than cycle exercise (p <

192 to airflow limitation and symptoms including breathlessness, wheeze, and chest tightness.

193 guidelines, the asthma symptoms are episodic breathlessness, wheeze, cough, tightness of the chest, a

194 G is involved with sensorimotor responses to breathlessness, while the vlPAG operates within the thre

195 lasma biomarker signature of disease linking breathlessness with apoptotic inflammatory networks cent

196 addition, participants who reported reduced breathlessness with morphine at 4 weeks also showed impr

197 Individual improvements in breathlessness with morphine may be related to improveme

198 shed disease, shorter walk distance, greater breathlessness, worse quality of life, and increased exa